Alzamend Neuro Establishes ATM Equity Offering Agreement

Alzamend Neuro ( (ALZN) ) has issued an update.

On March 6, 2026, Alzamend Neuro, Inc. entered into an at-the-market issuance sales agreement with Ascendiant Capital Markets, LLC to sell up to $3.0 million of its common stock from time to time. The shares will be issued under an existing shelf registration and prospectus supplement filed the same day, allowing the company to direct sales parameters such as volume, timing, and minimum price, with either party able to suspend or terminate the arrangement, providing flexible access to incremental capital for corporate needs.

Under the agreement, Ascendiant will use commercially reasonable efforts to execute sales of Alzamend’s stock in compliance with securities laws and Nasdaq rules. This financing structure gives Alzamend the ability to raise modest amounts of equity opportunistically in the market, potentially supporting its operational and development funding while offering investors an additional channel for trading its shares.

The most recent analyst rating on (ALZN) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Alzamend Neuro stock, see the ALZN Stock Forecast page.

More about Alzamend Neuro

Alzamend Neuro, Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and psychiatric disorders. The company operates in the life sciences and healthcare sector, using public equity markets, including shelf registrations and at-the-market offerings, to fund its research and development programs and ongoing operations.

Average Trading Volume: 73,210

Technical Sentiment Signal: Sell

Current Market Cap: $7.41M

For detailed information about ALZN stock, go to TipRanks’ Stock Analysis page.